verapamil has been researched along with Liver Dysfunction in 17 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Verapamil (CAS 52-53-9) is a calcium channel blocker with a vasodilatatory effect." | 2.68 | Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy. ( Brátová, M; Fendrich, Z; Hůlek, P; Macek, K; Vlcek, J, 1995) |
| "To determine whether verapamil, diltiazem, or nifedipine affect digitoxin kinetics, glycoside plasma concentrations and renal excretion were measured before and during steady-state dosing in 30 patients with cardiac insufficiency." | 2.66 | Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin. ( Kuhlmann, J, 1985) |
| " These products are well absorbed from the gastrointestinal tract but undergo variable degrees of transformation during the first passage through the liver." | 2.37 | [Clinical pharmacology of calcium inhibitors]. ( Martre, H; Singlas, E; Taburet, AM, 1985) |
| "Verapamil pretreatment increased the protein synthesis activity at both levels of granular endoplasmic reticulum and free polysomes in cytoplasm and decreased ATPase activity." | 1.31 | Evaluation of calcium channel blockers as potential hepatoprotective agents in oxidative stress injury of perfused hepatocytes. ( Farghali, H; Kmonícková, E; Lotková, H; Martínek, J, 2000) |
| "Verapamil kinetics have been determined in liver disease (mainly in cirrhotic patients), in intensive-care patients, and in healthy control subjects." | 1.26 | Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. ( Rietbrock, I; Rietbrock, N; Vöhringer, HF; Woodcock, BG, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (58.82) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manov, I | 1 |
| Motanis, H | 1 |
| Frumin, I | 1 |
| Iancu, TC | 1 |
| Kaplan, N | 1 |
| Yagmurdur, H | 1 |
| Kilinc, K | 1 |
| Baltaci, B | 1 |
| Tezel, S | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Rietbrock, N | 3 |
| Woodcock, BG | 3 |
| Rietbrock, I | 1 |
| Vöhringer, HF | 1 |
| Vlcek, J | 1 |
| Macek, K | 1 |
| Hůlek, P | 1 |
| Brátová, M | 1 |
| Fendrich, Z | 1 |
| Farghali, H | 1 |
| Kmonícková, E | 1 |
| Lotková, H | 1 |
| Martínek, J | 1 |
| Sahin, M | 1 |
| Başar, MM | 1 |
| Bozdoğan, O | 1 |
| Atan, A | 1 |
| Ishii, K | 1 |
| Arima, T | 1 |
| Suita, S | 1 |
| Rosansky, SJ | 1 |
| Lauterburg, BH | 1 |
| Padrini, R | 1 |
| Piovan, D | 1 |
| Bova, S | 1 |
| Moretto, R | 1 |
| Cargnelli, G | 1 |
| Ferrari, M | 1 |
| Kuhlmann, J | 1 |
| Singlas, E | 1 |
| Martre, H | 1 |
| Taburet, AM | 1 |
| Hare, DL | 1 |
| Horowitz, JD | 1 |
| Bruzzese, V | 1 |
| Coccia, G | 1 |
| Di Bartolomeo, R | 1 |
| Fiorini, G | 1 |
| Rossi, A | 1 |
| Ruggieri, P | 1 |
2 reviews available for verapamil and Liver Dysfunction
| Article | Year |
|---|---|
Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Ster | 2006 |
[Clinical pharmacology of calcium inhibitors].
Topics: Age Factors; Animals; Bepridil; Biological Availability; Biotransformation; Calcium Channel Blockers | 1985 |
2 trials available for verapamil and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy.
Topics: Adult; Aged; Antipyrine; Breath Tests; Female; Half-Life; Humans; Hypertension, Portal; Liver Diseas | 1995 |
Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin.
Topics: Aged; Benzazepines; Clinical Trials as Topic; Digitoxin; Diltiazem; Drug Interactions; Drug Therapy, | 1985 |
13 other studies available for verapamil and Liver Dysfunction
| Article | Year |
|---|---|
The protective effects of intravenous anesthetics and verapamil in gut ischemia/reperfusion-induced liver injury.
Topics: Anesthetics, Intravenous; Animals; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination | 2007 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
[Drugs with first-pass elimination. Verapamil and dihydroergotamine alkaloids].
Topics: Animals; Biological Availability; Dihydroergotoxine; Ergot Alkaloids; Humans; Kinetics; Liver; Liver | 1982 |
Verapamil bioavailability and dosage in liver disease.
Topics: Biological Availability; Humans; Liver Cirrhosis; Liver Diseases; Verapamil | 1982 |
Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.
Topics: Adolescent; Adult; Aged; Biological Availability; Critical Care; Humans; Kinetics; Liver Circulation | 1981 |
Evaluation of calcium channel blockers as potential hepatoprotective agents in oxidative stress injury of perfused hepatocytes.
Topics: Adenosine Triphosphatases; Animals; Calcium Channel Blockers; Chemical and Drug Induced Liver Injury | 2000 |
Short-term histopathologic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: an experimental study.
Topics: Alprostadil; Animals; Calcium Channel Blockers; Chemical and Drug Induced Liver Injury; Disease Mode | 2001 |
Verapamil attenuates postischemic oxidative injury in the rat liver.
Topics: Animals; Body Water; Infusions, Intravenous; L-Lactate Dehydrogenase; Lipid Peroxidation; Liver Dise | 1992 |
Verapamil toxicity and renal failure.
Topics: Acute Kidney Injury; Humans; Liver Diseases; Verapamil | 1992 |
[Clinical pharmacology of calcium antagonists].
Topics: Aging; Arrhythmias, Cardiac; Biological Availability; Calcium Channel Blockers; Diltiazem; Drug Inte | 1987 |
Physiological, pharmacological and pathological factors affecting the pharmacokinetics of calcium entry blockers.
Topics: Aging; Animals; Calcium Channel Blockers; Diltiazem; Drug Administration Schedule; Guinea Pigs; Huma | 1987 |
Verapamil hepatotoxicity: a hypersensitivity reaction.
Topics: Aged; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Humans; Liver Diseases; | 1986 |
[Acute unusual hemodynamic effects of the calcium-antagonists].
Topics: Aged; Asthenia; Bradycardia; Humans; Liver; Liver Diseases; Male; Middle Aged; Nifedipine; Verapamil | 1985 |